TVTX

Travere Therapeutics, Inc. (NASDAQ:TVTX) is a biopharmaceutical company founded in 2008 and headquartered in San Diego, California. Originally incorporated as Retrophin, Inc., the company rebranded to Travere Therapeutics in November 2020. The company specializes in developing and commercializing therapies for rare diseases, with a particular focus on rare kidney disorders and metabolic conditions. Travere has successfully transitioned from a development-stage company to a commercial-stage biopharmaceutical enterprise, with multiple approved products generating revenue and a robust pipeline of investigational therapies targeting significant unmet medical needs in rare disease populations.